Dr. Reddy's Laboratories’ business growth to be volatile in FY22

05 Jul 2021 Evaluate

Dr. Reddy's Laboratories is expecting its business growth to be volatile in FY22 as the coronavirus pandemic continues to bring in disruptions and impact the markets across the globe. Despite various challenges in the market, it has enough growth levers to deliver satisfactory performance in terms of business growth this fiscal.

For the 2020-21 fiscal year, the company posted a consolidated net profit of Rs 1,952 crore as against Rs 2,026 crore in 2019-20. Its net sales increased to Rs 18,420 crore during the last fiscal year as compared with Rs 16,357 crore in 2019-20.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1198.50 -25.80 (-2.11%)
29-Jan-2026 13:19 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1596.05
Dr. Reddys Lab 1198.50
Cipla 1317.50
Zydus Lifesciences 887.00
Lupin 2118.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×